AML-M0: a review of laboratory features and proposal of new diagnostic criteria.
In 1991, the FAB group published a proposal to designate acute leukemias with minimal signs of myeloid differentiation as AML-M0. This proposal was meant to offer a provisional basis for the study of immature myeloid forms, with the understanding that it was susceptible to changes and improvements with new information derived from the laboratory. Since then there have been a number of reports detailing the biological and clinical features of patients with AML-M0. In this article we review the laboratory data acquired from various sources and suggest a partial modification of diagnostic criteria.
Stasi
R
R
Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy. roberto.stasi@schering-plough.it
Amadori
S
S
D000208:Acute Disease; D001854:Bone Marrow Cells / Q000737:chemistry; D001856:Bone Marrow Examination; D003937:Diagnosis, Differential; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007951:Leukemia, Myeloid / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology